drugset / Trial / NCT06397963
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
Recruiting
18 enrolled
Grit Biotechnology
Beijing Arion Cancer Center · collabBeijing GoBroad Hospital · collabThe Affiliated Hospital of Xuzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Timeline
- Start
- 2024-04-18
- Primary completion
- 2027-04-18
- Completion
- 2027-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT307 | Cell therapy | — | — |